Abstract
Contrast-induced nephropathy (CIN) is the third most common cause of acute kidney injury in hospitalized patients. Diagnostic and interventional cardiovascular procedures generate nearly half the cases. Elderly patients and those with chronic kidney disease, diabetes, and cardiovascular disease are at greatest risk. Procedure-related risk factors include large volumes of contrast and agents with a high osmolality. Renal medullary ischemia arising from an imbalance of local vasoconstrictive and vasodilatory influences coupled with increased demand for oxygen-driven sodium transport may be the key to its pathogenesis. Contrast agents may also have a direct cytotoxic effect that operates through the generation of reactive oxygen species. Pre- and post-procedure administration of normal saline, isotonic sodium bicarbonate, N-acetylcysteine, and a variety of other pharmacologic agents have been used to prevent or mitigate CIN. While normal saline is generally accepted as protective against CIN, uncertainty still surrounds the role of sodium bicarbonate and N-acetylcysteine. Dialytic therapies before, during, and after exposure to contrast have been tested with mixed results. Logistical and economic disincentives argue against these modalities.
Similar content being viewed by others
References
American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2006) Heart disease and stroke statistics—2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113:e85–e151
Persson PB (2005) Editorial: contrast medium-induced nephropathy. Nephrol Dial Transplant 20[Suppl 1]:i1
Weisbord SD, Chen H, Stone RA, Kip KE, Fine MJ, Saul MI, Palevsky PM (2006) Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol 17:2871–2877
Liss P, Persson PB, Hansell P, Lagerqvist B (2006) Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int 70:1811–1817
McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW (1997) Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103:368–375
Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105:2259–2264
Solomon R, Barrett B (2006) Follow-up of patients with contrast-induced nephropathy. Kidney Int Suppl:S46–50
Katholi RE, Taylor GJ, Woods WT, Womack KA, Katholi CR, McCann WP, Moses HW, Dove JT, Mikell FL, Woodruff RC, Miller BD, Schneider JA (1993) Nephrotoxicity of nonionic low-osmolality versus ionic high-osmolality contrast media: a prospective double-blind randomized comparison in human beings. Radiology 186:183–187
Shah SH, Mehta RL (2006) Acute kidney injury in critical care: time for a paradigm shift? Curr Opin Nephrol Hypertens 15:561–565
Hoste EA, Kellum JA (2006) Acute kidney injury: epidemiology and diagnostic criteria. Curr Opin Crit Care 12:531–537
Rickli H, Benou K, Ammann P, Fehr T, Brunner-La Rocca HP, Petridis H, Riesen W, Wuthrich RP (2004) Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol 61:98–102
Hirsch R, Dent C, Pfriem H, Allen J, Beekman RH 3rd, Ma Q, Dastrala S, Bennett M, Mitsnefes M, Devarajan P (2007) NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 22:2089–2095
Chertow GM (1997) On the design and analysis of multicenter trials in acute renal failure. Am J Kidney Dis 30:S96–101
Nash K, Hafeez A, Hou S (2002) Hospital-acquired renal insufficiency. Am J Kidney Dis 39:930–936
Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT (1983) Hospital-acquired renal insufficiency: a prospective study. Am J Med 74:243–248
Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, Hill JA, Winniford M, Cohen MB, VanFossen DB (1995) Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 47:254–261
Manske CL, Sprafka JM, Strony JT, Wang Y (1990) Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 89:615–620
Yoshioka T, Fogo A, Beckman JK (1992) Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 41:1008–1015
McCarthy CS, Becker JA (1992) Multiple myeloma and contrast media. Radiology 183:519–521
Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV, Michelis MF (2008) The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol 40:749–755
Nikolsky E, Mehran R, Lasic Z, Mintz GS, Lansky AJ, Na Y, Pocock S, Negoita M, Moussa I, Stone GW, Moses JW, Leon MB, Dangas G (2005) Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 67:706–713
Ahuja TS, Niaz N, Agraharkar M (2000) Contrast-induced nephrotoxicity in renal allograft recipients. Clin Nephrol 54:11–14
Ranucci M, Ballotta A, Kunkl A, De Benedetti D, Kandil H, Conti D, Mollichelli N, Bossone E, Mehta RH (2008) Influence of the timing of cardiac catheterization and the amount of contrast media on acute renal failure after cardiac surgery. Am J Cardiol 101:1112–1118
Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, Grines CL, O’Neill WW (2004) Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 93:1515–1519
Arakawa K, Suzuki H, Naitoh M, Matsumoto A, Hayashi K, Matsuda H, Ichihara A, Kubota E, Saruta T (1996) Role of adenosine in the renal responses to contrast medium. Kidney Int 49:1199–1206
Workman RJ, Shaff MI, Jackson RV, Diggs J, Frazer MG, Briscoe C (1983) Relationship of renal hemodynamic and functional changes following intravascular contrast to the renin-angiotensin system and renal prostacyclin in the dog. Invest Radiol 18:160–166
Seeliger E, Flemming B, Wronski T, Ladwig M, Arakelyan K, Godes M, Mockel M, Persson PB (2007) Viscosity of contrast media perturbs renal hemodynamics. J Am Soc Nephrol 18:2912–2920
Weisberg LS, Kurnik PB, Kurnik BR (1992) Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction. Kidney Int 41:1408–1415
Mockel M, Radovic M, Kuhnle Y, Combe V, Waigand J, Schroder S, Dietz R, Frei U, Eckardt KU (2008) Acute renal haemodynamic effects of radiocontrast media in patients undergoing left ventricular and coronary angiography. Nephrol Dial Transplant 23:1588–1594
Heyman SN, Rosen S, Rosenberger C (2008) Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol 3:288–296
Brezis M, Rosen S (1995) Hypoxia of the renal medulla—its implications for disease. N Engl J Med 332:647–655
Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M (1994) Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 94:1069–1075
Heyman SN, Brezis M, Epstein FH, Spokes K, Silva P, Rosen S (1991) Early renal medullary hypoxic injury from radiocontrast and indomethacin. Kidney Int 40:632–642
Liss P, Nygren A, Erikson U, Ulfendahl HR (1998) Injection of low and iso-osmolar contrast medium decreases oxygen tension in the renal medulla. Kidney Int 53:698–702
Liss P, Carlsson PO, Palm F, Hansell P (2004) Adenosine A1 receptors in contrast media-induced renal dysfunction in the normal rat. Eur Radiol 14:1297–1302
Agmon Y, Dinour D, Brezis M (1993) Disparate effects of adenosine A1- and A2-receptor agonists on intrarenal blood flow. Am J Physiol 265:F802–806
Kubo SH, Rector TS, Bank AJ (1996) Endothelial nitric oxide pathway function in the peripheral vasculature of patients with heart failure. J Card Fail 2:S217–223
Zoccali C (2006) Endothelial dysfunction and the kidney: emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. J Am Soc Nephrol 17:S61–63
Calver A, Collier J, Vallance P (1992) Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 90:2548–2554
Panza JA, Quyyumi AA, Callahan TS, Epstein SE (1993) Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 21:1145–1151
Liss P, Carlsson PO, Nygren A, Palm F, Hansell P (2003) Et-A receptor antagonist BQ123 prevents radiocontrast media-induced renal medullary hypoxia. Acta Radiol 44:111–117
Heyman SN, Clark BA, Kaiser N, Spokes K, Rosen S, Brezis M, Epstein FH (1992) Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol 3:58–65
Touyz RM (2004) Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 44:248–252
Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D (2006) Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 48:752–760
White M, Ducharme A, Ibrahim R, Whittom L, Lavoie J, Guertin MC, Racine N, He Y, Yao G, Rouleau JL, Schiffrin EL, Touyz RM (2006) Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clin Sci (Lond) 110:483–489
Hayden MR, Whaley-Connell A, Sowers JR (2005) Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol 25:553–569
Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr (1990) Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 258:F115–120
Araujo M, Welch WJ (2006) Oxidative stress and nitric oxide in kidney function. Curr Opin Nephrol Hypertens 15:72–77
Itoh Y, Yano T, Sendo T, Sueyasu M, Hirano K, Kanaide H, Oishi R (2006) Involvement of de novo ceramide synthesis in radiocontrast-induced renal tubular cell injury. Kidney Int 69:288–297
Schick CS, Haller C (1999) Comparative cytotoxicity of ionic and non-ionic radiocontrast agents on MDCK cell monolayers in vitro. Nephrol Dial Transplant 14:342–347
Peer A, Averbukh Z, Berman S, Modai D, Averbukh M, Weissgarten J (2003) Contrast media augmented apoptosis of cultured renal mesangial, tubular, epithelial, endothelial, and hepatic cells. Invest Radiol 38:177–182
Haller C, Hizoh I (2004) The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro. Invest Radiol 39:149–154
Dobrota M, Powell CJ, Holtz E, Wallin A, Vik H (1995) Biochemical and morphological effects of contrast media on the kidney. Acta Radiol Suppl 399:196–203
Ueda J, Nygren A, Hansell P, Erikson U (1992) Influence of contrast media on single nephron glomerular filtration rate in rat kidney. A comparison between diatrizoate, iohexol, ioxaglate, and iotrolan. Acta Radiol 33:596–599
Ueda J, Nygren A, Hansell P, Ulfendahl HR (1993) Effect of intravenous contrast media on proximal and distal tubular hydrostatic pressure in the rat kidney. Acta Radiol 34:83–87
Ueda J, Nygren A, Sjoquist M, Jacobsson E, Ulfendahl HR, Araki Y (1998) Iodine concentrations in the rat kidney measured by X-ray microanalysis. Comparison of concentrations and viscosities in the proximal tubules and renal pelvis after intravenous injections of contrast media. Acta Radiol 39:90–95
Persson PB, Tepel M (2006) Contrast medium-induced nephropathy: the pathophysiology. Kidney Int Suppl 100:S8–10
Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, Lansky AJ, Tsounias E, Moses JW, Stone GW, Leon MB, Dangas GD (2004) Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 94:300–305
Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS (2008) Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. J Am Coll Cardiol 51:89–90
Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, Moltrasio M, Grazi M, Rubino M, Veglia F, Fabbiocchi F, Bartorelli AL (2009) Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med 150:170–177
Barrett BJ, Carlisle EJ (1993) Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 188:171–178
Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ (2003) Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348:491–499
McCullough PA, Bertrand ME, Brinker JA, Stacul F (2006) A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 48:692–699
Heinrich MC, Haberle L, Muller V, Bautz W, Uder M (2009) Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology 250:68–86
Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, Heiken JP, Lepanto L, Ni ZH, Ni ZH, Nelson R (2006) Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol 41:815–821
Kuhn MJ, Chen N, Sahani DV, Reimer D, van Beek EJ, Heiken JP, So GJ (2008) The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. AJR Am J Roentgenol 191:151–157
Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, Marsch S, Roskamm H (2002) Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162:329–336
Solomon R, Werner C, Mann D, D’Elia J, Silva P (1994) Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331:1416–1420
Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, Hewett J (2003) A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 93:C29–34
Weisbord SD, Bruns FJ, Saul MI, Palevsky PM (2004) Provider use of preventive strategies for radiocontrast nephropathy in high-risk patients. Nephron Clin Pract 96:c56–62
Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP (2004) Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291:2328–2334
Masuda M, Yamada T, Mine T, Morita T, Tamaki S, Tsukamoto Y, Okuda K, Iwasaki Y, Hori M, Fukunami M (2007) Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol 100:781–786
Hogan SE, L’Allier P, Chetcuti S, Grossman PM, Nallamothu BK, Duvernoy C, Bates E, Moscucci M, Gurm HS (2008) Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. Am Heart J 156:414–421
Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Bellandi F (2008) Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol 52:599–604
From AM, Bartholmai BJ, Williams AW, Cha SS, Pflueger A, McDonald FS (2008) Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at mayo clinic. Clin J Am Soc Nephrol 3:10–18
Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343:180–184
Efrati S, Dishy V, Averbukh M, Blatt A, Krakover R, Weisgarten J, Morrow JD, Stein MC, Golik A (2003) The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int 64:2182–2187
Fiaccadori E, Maggiore U, Rotelli C, Giacosa R, Lombardi M, Sagripanti S, Buratti S, Ardissino D, Cabassi A (2004) Plasma and urinary free 3-nitrotyrosine following cardiac angiography procedures with non-ionic radiocontrast media. Nephrol Dial Transplant 19:865–869
Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Cesar LA, Seguro AC (2004) Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 19:1803–1807
Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF (2003) Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 289:553–558
Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL (2006) N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354:2773–2782
Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ (2003) A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 41:2114–2118
Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK (2004) The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15:407–410
Bagshaw SM, McAlister FA, Manns BJ, Ghali WA (2006) Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med 166:161–166
Nallamothu BK, Shojania KG, Saint S, Hofer TP, Humes HD, Moscucci M, Bates ER (2004) Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med 117:938–947
Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC (2008) Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 148:284–294
Fishbane S (2008) N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol 3:281–287
Vaitkus PT, Brar C (2007) N-acetylcysteine in the prevention of contrast-induced nephropathy: publication bias perpetuated by meta-analyses. Am Heart J 153:275–280
Kanter MZ (2006) Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning. Am J Health Syst Pharm 63:1821–1827
Katholi RE, Taylor GJ, McCann WP, Woods WT Jr, Womack KA, McCoy CD, Katholi CR, Moses HW, Mishkel GJ, Lucore CL, Holloway RM, Miller BD, Woodruff RC, Dove JT, Mikell FL, Schneider JA (1995) Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 195:17–22
Shammas NW, Kapalis MJ, Harris M, McKinney D, Coyne EP (2001) Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invasive Cardiol 13:738–740
Bagshaw SM, Ghali WA (2005) Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med 165:1087–1093
Huber W, Eckel F, Hennig M, Rosenbrock H, Wacker A, Saur D, Sennefelder A, Hennico R, Schenk C, Meining A, Schmelz R, Fritsch R, Weiss W, Hamar P, Heemann U, Schmid RM (2006) Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 239:793–804
Gurkowski L, MacDougall M, Wiegmann T (1995) Effects of misoprostol on contrast-induced renal dysfunction. Am J Ther 2:837–842
Koch JA, Plum J, Grabensee B, Modder U (2000) Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol Dial Transplant 15:43–49
Sketch MH Jr, Whelton A, Schollmayer E, Koch JA, Bernink PJ, Woltering F, Brinker J (2001) Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study. Am J Ther 8:155–162
Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, Voudris V, Pavlides G, Buller CE, Kremastinos D, Cokkinos DV (2004) Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 110:2837–2842
Briguori C, Airoldi F, D’Andrea D, Bonizzoni E, Morici N, Focaccio A, Michev I, Montorfano M, Carlino M, Cosgrave J, Ricciardelli B, Colombo A (2007) Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115:1211–1217
Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK (2002) Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 57:279–283
Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, Wang A, Chu AA, Schaer GL, Stevens M, Wilensky RL, O’Neill WW (2003) Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290:2284–2291
Hans SS, Hans BA, Dhillon R, Dmuchowski C, Glover J (1998) Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am Surg 64:432–436
Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD, Satler LF, Harvey M, Kent KM, Leon MB (1999) Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 83(260–263):A265
Weisberg LS, Kurnik PB, Kurnik BR (1994) Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 45:259–265
Gare M, Haviv YS, Ben-Yehuda A, Rubinger D, Bdolah-Abram T, Fuchs S, Gat O, Popovtzer MM, Gotsman MS, Mosseri M (1999) The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 34:1682–1688
Cacoub P, Deray G, Baumelou A, Jacobs C (1988) No evidence for protective effects of nifedipine against radiocontrast-induced acute renal failure. Clin Nephrol 29:215–216
Russo D, Testa A, Della Volpe L, Sansone G (1990) Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron 55:254–257
Carraro M, Mancini W, Artero M, Stacul F, Grotto M, Cova M, Faccini L (1996) Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Nephrol Dial Transplant 11:444–448
Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS (1998) Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 31:674–680
Miller HI, Dascalu A, Rassin TA, Wollman Y, Chernichowsky T, Iaina A (2003) Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, double-blind clinical trial. Am J Nephrol 23:91–95
Attallah N, Yassine L, Musial J, Yee J, Fisher K (2004) The potential role of statins in contrast nephropathy. Clin Nephrol 62:273–278
Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O’Donnell MJ, Moscucci M (2005) Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 118:843–849
Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, Youn TJ, Chung WY, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS (2008) Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial–a randomized controlled study. Am Heart J 155:e491–498
Weinstein JM, Heyman S, Brezis M (1992) Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 62:413–415
Anto HR, Chou SY, Porush JG, Shapiro WB (1981) Infusion intravenous pyelography and renal function. Effect of hypertonic mannitol in patients with chronic renal insufficiency. Arch Intern Med 141:1652–1656
Wang A, Holcslaw T, Bashore TM, Freed MI, Miller D, Rudnick MR, Szerlip H, Thames MD, Davidson CJ, Shusterman N, Schwab SJ (2000) Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 57:1675–1680
Schindler R, Stahl C, Venz S, Ludat K, Krause W, Frei U (2001) Removal of contrast media by different extracorporeal treatments. Nephrol Dial Transplant 16:1471–1474
Lehnert T, Keller E, Gondolf K, Schaffner T, Pavenstadt H, Schollmeyer P (1998) Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 13:358–362
Sterner G, Frennby B, Kurkus J, Nyman U (2000) Does post-angiographic hemodialysis reduce the risk of contrast-medium nephropathy? Scand J Urol Nephrol 34:323–326
Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M, Cereghetti C, Serra A, Huynh-Do U, Uehlinger D, Frey FJ (2001) Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 111:692–698
Frank H, Werner D, Lorusso V, Klinghammer L, Daniel WG, Kunzendorf U, Ludwig J (2003) Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol 60:176–182
Lee PT, Chou KJ, Liu CP, Mar GY, Chen CL, Hsu CY, Fang HC, Chung HM (2007) Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol 50:1015–1020
Gabutti L, Marone C, Monti M, Malfanti M, Zwahlen U, Pasotti E, Colucci G, Schonholzer C (2003) Does continuous venovenous hemodiafiltration concomitant with radiological procedures provide a significant and safe removal of the iodinated contrast ioversol? Blood Purif 21:152–157
Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, Trabattoni D, Fabbiocchi F, Montorsi P, Bartorelli AL (2003) The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 349:1333–1340
Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, Grazi M, Veglia F, Fabbiocchi F, Montorsi P, Bartorelli AL (2006) Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 119:155–162
Klarenbach SW, Pannu N, Tonelli MA, Manns BJ (2006) Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease. Crit Care Med 34:1044–1051
Younathan CM, Kaude JV, Cook MD, Shaw GS, Peterson JC (1994) Dialysis is not indicated immediately after administration of nonionic contrast agents in patients with end-stage renal disease treated by maintenance dialysis. AJR Am J Roentgenol 163:969–971
Hamani A, Petitclerc T, Jacobs C, Deray G (1998) Is dialysis indicated immediately after administration of iodinated contrast agents in patients on haemodialysis? Nephrol Dial Transplant 13:1051–1052
Morcos SK, Thomsen HS, Webb JA (2002) Dialysis and contrast media. Eur Radiol 12:3026–3030
Sam AD 2nd, Morasch MD, Collins J, Song G, Chen R, Pereles FS (2003) Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 38:313–318
Nyman U, Elmstahl B, Leander P, Nilsson M, Golman K, Almen T (2002) Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia? Radiology 223:311–318 discussion 328-329
Thomsen HS (2005) How to avoid CIN: guidelines from the European Society of Urogenital Radiology. Nephrol Dial Transplant 20[Suppl 1]:i18–22
Medwatch F (2006) Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Ominiscan, OptiMARK, Magnevist, ProHance, and MultiHance. Available at: https://doi.org/FDA.GOV/medwatch/safety/2006/safety06.htm
Grobner T (2006) Gadolinium–a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108
Boyd AS, Zic JA, Abraham JL (2007) Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56:27–30
Penfield JG, Reilly RF (2008) Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 21:129–134
Solomon R, Deray G (2006) How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl 69[Suppl S100]:S51–S53
Goldfarb S, McCullough PA, McDermott J, Gay SB (2009) Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc 84:170–179
Arend LJ, Bakris GL, Burnett JC Jr, Megerian C, Spielman WS (1987) Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med 110:406–411
Erley C (2006) Concomitant drugs with exposure to contrast media. Kidney Int Suppl 69:S20–S24
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cronin, R.E. Contrast-induced nephropathy: pathogenesis and prevention. Pediatr Nephrol 25, 191–204 (2010). https://doi.org/10.1007/s00467-009-1204-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-009-1204-z